MX2010001390A - Métodos para el tratamiento de dependencia. - Google Patents
Métodos para el tratamiento de dependencia.Info
- Publication number
- MX2010001390A MX2010001390A MX2010001390A MX2010001390A MX2010001390A MX 2010001390 A MX2010001390 A MX 2010001390A MX 2010001390 A MX2010001390 A MX 2010001390A MX 2010001390 A MX2010001390 A MX 2010001390A MX 2010001390 A MX2010001390 A MX 2010001390A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating
- dependence
- substance
- patients
- Prior art date
Links
- 239000000126 substance Substances 0.000 abstract 2
- 208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 201000006145 cocaine dependence Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 201000006152 substance dependence Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93532307P | 2007-08-06 | 2007-08-06 | |
| US95655507P | 2007-08-17 | 2007-08-17 | |
| US96059107P | 2007-10-04 | 2007-10-04 | |
| PCT/US2008/072357 WO2009021055A1 (en) | 2007-08-06 | 2008-08-06 | Methods for treating dependence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010001390A true MX2010001390A (es) | 2010-08-02 |
Family
ID=40341713
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001390A MX2010001390A (es) | 2007-08-06 | 2008-08-06 | Métodos para el tratamiento de dependencia. |
| MX2015009454A MX357542B (es) | 2007-08-06 | 2008-08-06 | Nepicastat para usarse en el tratamiento de dependencia. |
| MX2018008628A MX391921B (es) | 2007-08-06 | 2008-08-06 | Nepicastat para usarse en el tratamiento de dependencia |
| MX2022001510A MX2022001510A (es) | 2007-08-06 | 2010-02-04 | Nepicastat para usarse en el tratamiento de dependencia. |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009454A MX357542B (es) | 2007-08-06 | 2008-08-06 | Nepicastat para usarse en el tratamiento de dependencia. |
| MX2018008628A MX391921B (es) | 2007-08-06 | 2008-08-06 | Nepicastat para usarse en el tratamiento de dependencia |
| MX2022001510A MX2022001510A (es) | 2007-08-06 | 2010-02-04 | Nepicastat para usarse en el tratamiento de dependencia. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20090041800A1 (enExample) |
| EP (2) | EP2182804B1 (enExample) |
| JP (5) | JP2010535801A (enExample) |
| CN (2) | CN101815438A (enExample) |
| AU (1) | AU2008283903B2 (enExample) |
| BR (1) | BRPI0815089A2 (enExample) |
| CA (1) | CA2695372C (enExample) |
| CO (1) | CO6260015A2 (enExample) |
| ES (1) | ES2638190T3 (enExample) |
| IL (1) | IL257418A (enExample) |
| MX (4) | MX2010001390A (enExample) |
| NZ (1) | NZ583192A (enExample) |
| PH (1) | PH12015502210A1 (enExample) |
| RU (1) | RU2491067C2 (enExample) |
| SG (2) | SG10201705968RA (enExample) |
| WO (1) | WO2009021055A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2491067C2 (ru) | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
| WO2010124089A2 (en) * | 2009-04-22 | 2010-10-28 | Synosia Therapeutics, Inc. | Methods for treating dependence |
| US9804149B2 (en) * | 2012-10-10 | 2017-10-31 | Bio-Rad Laboratories, Inc. | Patient-based results display |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US20170235908A1 (en) * | 2015-11-15 | 2017-08-17 | Oriah Behaviorial Health, Inc. | Systems and Methods for Managing and Treating Substance Abuse Addiction |
| CN110996912A (zh) * | 2017-08-20 | 2020-04-10 | 福摩莱克斯医药创新有限公司 | 用于鼻内递送的干粉组合物 |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| CN108066355A (zh) * | 2017-12-28 | 2018-05-25 | 宁夏恩多芬科技有限公司 | Nitrous Oxide作为治疗神经官能症的用途 |
| FR3093419B1 (fr) * | 2019-03-08 | 2021-06-18 | Univ Grenoble Alpes | Composition et procédé associé de mesure de l’observance thérapeutique |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| HRP20220797T1 (hr) * | 2019-11-07 | 2022-10-14 | Small Pharma Ltd | Spojevi |
| WO2021168133A1 (en) | 2020-02-19 | 2021-08-26 | Nevakar Inc. | Isoproterenol compositions and methods |
| US11400045B2 (en) | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| KR20230071131A (ko) * | 2020-08-17 | 2023-05-23 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | 도파민 기능의 바이오마커로서 뉴로멜라닌-민감성 mri의 용도 |
| EP4222501A1 (en) * | 2020-10-24 | 2023-08-09 | Universitätsspital Basel | Method of quantifying lysergic acid diethylamide (lsd) and 2,3-dihydro-3-hydroxy-2-oxo lysergide (o-h-lsd) in human plasma |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112690771B (zh) * | 2020-12-09 | 2022-05-24 | 华南理工大学 | 一种利用线性回归模型的人脸视频心率检测方法 |
| CN117098496A (zh) | 2021-03-11 | 2023-11-21 | 人类生物科学股份有限公司 | 用于协调包括生物标志物的成像数据集的系统、装置和方法 |
| CN113017632B (zh) * | 2021-03-17 | 2022-11-11 | 陈思 | 一种智慧校园心理咨询辅助方法及系统 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2024056079A1 (zh) | 2022-09-16 | 2024-03-21 | 江苏亚虹医药科技股份有限公司 | 内匹司他酸加成盐的多晶型及其制备方法和用途 |
| WO2024178082A2 (en) * | 2023-02-22 | 2024-08-29 | Freedom Biosciences, Inc. | Composition of opioid receptor modulator and mdma for use thereof |
| CN120754106B (zh) * | 2025-09-02 | 2025-12-09 | 合肥工业大学 | 化合物sch23390在制备治疗铅中毒药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03500411A (ja) * | 1987-10-07 | 1991-01-31 | マトリックス テクノロジーズ インコーポレーテッド | コカイン中毒の処置および治療薬 |
| US5593367A (en) * | 1995-08-18 | 1997-01-14 | Deere & Company | Switchable ignition and starter control system |
| CA2247468A1 (en) * | 1996-02-23 | 1997-08-28 | Mark Froimowitz | Selective d1 dopamine receptor agonists and partial agonists/antagonists |
| US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| NZ539400A (en) * | 2001-01-17 | 2006-04-28 | Hythiam Inc | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
| AU2002245613A1 (en) * | 2001-03-07 | 2002-09-24 | The Mclean Hospital Corporation | Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| CA2516618A1 (en) * | 2003-02-27 | 2004-09-10 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Pharmaceutical composition for treatment of drug dependence |
| RU2252756C1 (ru) * | 2003-12-23 | 2005-05-27 | Хохлов Александр Петрович | Препарат против алкоголизма и наркомании, способ получения такого препарата |
| US20100105748A1 (en) * | 2007-03-16 | 2010-04-29 | David Weinshenker | Methods and compositions for treatment of drug addiction |
| MX2010000938A (es) * | 2007-07-23 | 2010-07-01 | Synosia Therapeutics Inc | Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático. |
| NZ583193A (en) * | 2007-07-23 | 2012-05-25 | Biotie Therapies Inc | Treatment of post-traumatic stress disorder with nepicastat |
| WO2009015244A1 (en) * | 2007-07-23 | 2009-01-29 | Synosia Therapeutics | Rufinamide for the treatment of post-traumatic stress disorder |
| RU2491067C2 (ru) | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
| CN101874128B (zh) | 2007-11-26 | 2012-07-04 | 株式会社普利司通 | 铜-锌合金电镀浴及使用其的镀敷方法 |
-
2008
- 2008-08-06 RU RU2010108249/15A patent/RU2491067C2/ru active
- 2008-08-06 EP EP08797300.4A patent/EP2182804B1/en not_active Not-in-force
- 2008-08-06 ES ES08797300.4T patent/ES2638190T3/es active Active
- 2008-08-06 MX MX2010001390A patent/MX2010001390A/es not_active Application Discontinuation
- 2008-08-06 JP JP2010520285A patent/JP2010535801A/ja active Pending
- 2008-08-06 SG SG10201705968RA patent/SG10201705968RA/en unknown
- 2008-08-06 MX MX2015009454A patent/MX357542B/es unknown
- 2008-08-06 CN CN200880109939A patent/CN101815438A/zh active Pending
- 2008-08-06 BR BRPI0815089-3A2A patent/BRPI0815089A2/pt not_active IP Right Cessation
- 2008-08-06 CN CN201611204491.7A patent/CN106983747A/zh active Pending
- 2008-08-06 WO PCT/US2008/072357 patent/WO2009021055A1/en not_active Ceased
- 2008-08-06 US US12/187,166 patent/US20090041800A1/en not_active Abandoned
- 2008-08-06 AU AU2008283903A patent/AU2008283903B2/en not_active Ceased
- 2008-08-06 SG SG2012058210A patent/SG183696A1/en unknown
- 2008-08-06 MX MX2018008628A patent/MX391921B/es unknown
- 2008-08-06 CA CA2695372A patent/CA2695372C/en not_active Expired - Fee Related
- 2008-08-06 NZ NZ583192A patent/NZ583192A/en not_active IP Right Cessation
- 2008-08-06 EP EP17165804.0A patent/EP3251670A1/en not_active Withdrawn
-
2010
- 2010-02-04 MX MX2022001510A patent/MX2022001510A/es unknown
- 2010-02-26 CO CO10023191A patent/CO6260015A2/es not_active Application Discontinuation
-
2013
- 2013-12-06 US US14/099,882 patent/US10561638B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 JP JP2014107381A patent/JP2014148551A/ja active Pending
-
2015
- 2015-09-22 PH PH12015502210A patent/PH12015502210A1/en unknown
-
2016
- 2016-08-23 JP JP2016162881A patent/JP2016210798A/ja active Pending
-
2018
- 2018-02-08 IL IL257418A patent/IL257418A/en unknown
- 2018-06-06 JP JP2018108758A patent/JP2018154645A/ja active Pending
-
2020
- 2020-01-07 US US16/736,609 patent/US20200383951A1/en not_active Abandoned
- 2020-05-01 JP JP2020081105A patent/JP2020114883A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3251670A1 (en) | 2017-12-06 |
| JP2020114883A (ja) | 2020-07-30 |
| US20140099336A1 (en) | 2014-04-10 |
| EP2182804B1 (en) | 2017-05-24 |
| SG10201705968RA (en) | 2017-08-30 |
| JP2010535801A (ja) | 2010-11-25 |
| ES2638190T3 (es) | 2017-10-19 |
| CN106983747A (zh) | 2017-07-28 |
| PH12015502210A1 (en) | 2017-04-10 |
| JP2014148551A (ja) | 2014-08-21 |
| NZ583192A (en) | 2012-06-29 |
| MX357542B (es) | 2018-07-13 |
| WO2009021055A1 (en) | 2009-02-12 |
| IL257418A (en) | 2018-04-30 |
| US20200383951A1 (en) | 2020-12-10 |
| CO6260015A2 (es) | 2011-03-22 |
| CN101815438A (zh) | 2010-08-25 |
| BRPI0815089A2 (pt) | 2014-09-30 |
| CA2695372A1 (en) | 2009-02-12 |
| MX391921B (es) | 2025-03-21 |
| JP2018154645A (ja) | 2018-10-04 |
| JP2016210798A (ja) | 2016-12-15 |
| SG183696A1 (en) | 2012-09-27 |
| MX2022001510A (es) | 2022-08-11 |
| RU2491067C2 (ru) | 2013-08-27 |
| AU2008283903A1 (en) | 2009-02-12 |
| US20090041800A1 (en) | 2009-02-12 |
| CA2695372C (en) | 2013-01-22 |
| EP2182804A4 (en) | 2010-12-22 |
| AU2008283903B2 (en) | 2014-01-16 |
| RU2010108249A (ru) | 2011-09-20 |
| US10561638B2 (en) | 2020-02-18 |
| EP2182804A1 (en) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502210A1 (en) | Method for treating dependence | |
| WO2010124089A3 (en) | Nepicastat for treating dependence | |
| EP2079500A4 (en) | DEVICES AND METHODS FOR INFUSION | |
| MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
| WO2007081879A3 (en) | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis | |
| EP2312993A4 (en) | DEVICES, METHODS AND KITS FOR FORMING TISSUE TRAYS | |
| EP2203169A4 (en) | GLYCEMIC INSPECTION, DIABETES TREATMENT, AND OTHER TREATMENTS WITH ACETYLCHOLINESTERASE INHIBITORS | |
| MX337586B (es) | Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta. | |
| WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
| IL202626A0 (en) | Method for treating an at least partially metallized textile, treated textile and the use thereof | |
| ZA201005905B (en) | Methods,dosage forms,and kits for administering ziprasidone without food | |
| MX2011006725A (es) | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. | |
| WO2010052312A8 (fr) | Medicament ou composition dermatologique comprenant un extrait peptidique d'avocat destine au traitement et a la prevention du prurit | |
| WO2009101199A3 (en) | Treatment of acne vulgaris; rosacea and rhinophym | |
| EP2371340A4 (en) | DRUG-RELATED DRUG-RELATED DRUG REDUCTION INSTRUMENT, METHOD OF USE THEREOF, AND METHOD OF TREATING ADDICTION-RELATIVE DRUGS DEPENDENCE | |
| MX2009012957A (es) | Metodo para tratar diabetes. | |
| EP2377267A4 (en) | Key issuer, key carrier, access unit and methods performed in said units | |
| UA36369U (ru) | Способ лечения артериальной гипертензии на санаторно-курортном этапе | |
| UA36375U (ru) | Способ лечения хронического рецидивирующего кандидозного вульвовагинита | |
| IL196633A0 (en) | An anaerobic digester and a method for treating sludge in the digester | |
| WO2010030653A3 (en) | Nurr1 interacting protein (nuip) | |
| WO2009073586A8 (en) | Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels | |
| UA34799U (ru) | Способ профилактики обострений параноидной шизофрении | |
| Lee | A Study on the Problems and Improvements of BTL Project Process | |
| de MORAGAS | Communication and the Olympic Games |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: BIOTIE THERAPIES, INC.* |
|
| FC | Refusal |